Eosinophils and Chronic Respiratory Diseases in Hospitalized COVID-19 Patients

Valverde‐Monge, Marcela; Cañas, J. A.; Barroso, Blanca; Betancor, Diana; Ortega-Martín, L; Gómez-López, Alicia; Rodríguez-Nieto, María Jesús; Mahíllo‐Fernández, Ignacio; Sastre, Joaquı́n; Pozo, Victoria del

doi:10.3389/fimmu.2021.668074

Cited by 14 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding eosinophils, the mean absolute eosinophil count (AEC) in our COVID-19 asthmatic patients was low (50.4 ± 110.3). Eosinopenia is a common finding in COVID-19 disease 1 probably related to worse outcomes in asthmatic patients, 21 , 22 nonetheless, in our cohort of patients with asthma we did not find significant differences in absolute eosinophil count on admission in terms of outcomes, as in previous reports. 27 …”

Section: Discussionsupporting

confidence: 80%

Clinical Features and Outcomes Associated with Bronchial Asthma Among COVID-19 Hospitalized Patients

Diaz¹,

Catalan-Caceres²,

Beauperthuy³

et al. 2022

JAA

View full text Add to dashboard Cite

Background The impact of diagnosis treatment and bronchial asthma on coronavirus disease 2019 (COVID-19) associated outcomes remains unclear. Objective To identify the prevalence and outcomes associated with asthma among hospitalized patients with COVID-19. Methods Electronic health records of 130 patients with asthma among hospitalized patients with COVID-19 were reviewed. Two subgroups of asthmatic patients were compared according to clinical outcomes during hospitalization. Patients with death results, intubation, and/or need of intensive care unit (ICU) stay were grouped as asthmatic patients with severe COVID-19 outcomes, and the rest were grouped as asthmatic patients with non-severe COVID-19 outcomes. Multivariable analyses were conducted with logistic regression to identify independent risk factors for severe outcomes. Results The prevalence of asthma in COVID-19 hospitalized patients was 5%. The mean age was 59.4 years and 54% were women. 17% received treatment in GINA step 4–5 asthma at the time of admission. An allergic asthma phenotype was determined in 38%. There was no significant difference in hospital length of stay or need for intubation between asthmatic patients and global COVID-19 admitted patients. 17% of asthmatic patients developed a severe outcome, and 5% had a death result. Elevated Lactate Dehydrogenase (LDH) level, low transcutaneous pulse oximetry (SpO2), the coexistence of atrial fibrillation (AF), and need for moderate or high ICS at admission were independent risk factors for a worse outcome in asthmatics COVID-19 hospitalized patients. Conclusion The prevalence of asthma in COVID-19 hospitalized patients was 5%, consistent with the asthma prevalence in the general population. The asthmatic patients with the previous prescription of moderate or high doses of ICS and/or coexistence of atrial fibrillation at admission had a higher risk of the severe outcome.

show abstract

Section: Discussionsupporting

confidence: 80%

Clinical Features and Outcomes Associated with Bronchial Asthma Among COVID-19 Hospitalized Patients

Diaz¹,

Catalan-Caceres²,

Beauperthuy³

et al. 2022

JAA

View full text Add to dashboard Cite

show abstract

“…Eosinopenia is known to be a severity predictor in COVID-19 disease. 12,13 In our cohort, asthmatic patients developed more eosinopenia and their recovery was lower compared to that of the nonasthmatic group. To date, no other studies have published similar data, and no relationship has access between COVID-19 disease, asthma, and eosinopenia.…”

mentioning

confidence: 65%

COVID‐19 and childhood asthma: Analysis of a pediatric referral hospital

Bartha

Bernaola

Escudero

et al. 2022

Pediatric Allergy Immunology

View full text Add to dashboard Cite

To the Editor, Spain has been one of the epicenters of the SARS-CoV-2 pandemic.Children (0-14 years-old) account at least for 10.5% of all cases and usually develop mild severity of coronavirus disease 20191 Clinical observations point out allergy and/or asthma are not risky conditions in pediatric patients with COVID-19, 2 and hypothetically, allergic sensitization could be inversely related to the expression of COVID-19. 3 However, little is known about the effect of SARS-CoV-2 infection in allergic and/or asthmatic children and adolescents. This study, approved by the Ethics Committee of Hospital Niño Jesús (Madrid, Spain), aimed to evaluate allergic comorbidities among symptomatic COVID-19 children attended at a referral pediatric hospital for this disease. The database of positive SARS-CoV-2 cases diagnosed based on reverse transcription polymerase chain reaction (RT-PCR) between 20 March and 13 July 2020 was retrospectively reviewed. Demographic information, COVID-19 symptoms, disease severity, clinical course, comorbidities, and blood biomarkers were obtained from electronic medical records. Eosinopenia was defined as absolute eosinophil counts ≤0.05 × 10 9 cells/L. Information on allergic disorders was obtained by telephone interview with parents and patients, who provided their oral consent to participate. The

show abstract

“…Furthermore, downregulation of specialized pro-resolving lipid mediators also contributes to increased disease severity and dysregulated phagocyte function in COVID-19 ( 110 ). Recent studies have suggested that eosinopenia confers a higher risk of severe progression ( 111 ). The nasopharyngeal microbiome has been shown to regulate local and systemic immune responses and impact disease outcomes in acute SARS-CoV-2 infection ( 112 , 113 ).…”

Section: Immune Response To Sars-cov-2 In the Lungmentioning

confidence: 99%